Wednesday, April 30th, 2025

China Tobacco International HK Co Ltd: Seizing Opportunities with Strategic Technical Buy Signals

Broker Name: CGS International Securities Singapore Pte. Ltd.
Date: October 21, 2024


Overview

China Tobacco International HK Co Ltd (Stock Code: 6055) is engaged in the production and distribution of tobacco products. The company is positioned to capitalize on market opportunities through strategic investments and operational efficiencies.

Investment Recommendation

  • Recommendation: Technical Buy
  • Entry Prices:
    • S$21.95
    • S$20.00
    • S$16.80
  • Stop Loss: S$15.50

Target Prices

  • Target Prices:
    • Target 1: S$24.80
    • Target 2: S$26.00
    • Target 3: S$30.50
    • Target 4: S$33.50

Technical Analysis

China Tobacco International HK Co Ltd is showing promising technical indicators that suggest potential price appreciation. The specified entry prices, along with the stop loss and target prices, provide a structured investment approach for potential buyers.

Summary

The strategic buy recommendation for China Tobacco International HK Co Ltd highlights its potential for growth and profitability in the tobacco sector. Investors are advised to consider the outlined entry points and target prices for optimal investment decisions.

LPN Development Q3 Earnings Miss: Residential Business Struggles Amid Economic Headwinds

Regional Morning Notes: Comprehensive Analysis of LPN Development Regional Morning Notes: Comprehensive Analysis of LPN Development Broker: UOB Kay Hian Date: Friday, 08 November 2024 Introduction Welcome to the latest edition of the Regional...

Haier Smart Home: A Key Beneficiary of China’s Consumption-Boosting Measures

Date: 7 October 2024Broker: OCBC Investment Research Company Overview Haier Smart Home, one of China’s top white goods/home appliances companies, has evolved from a refrigerator company in the 1980s into a global leader in...

Anteris Technologies IPO: A Game-Changer in Heart Valves, Oversubscribed by 9x

1. IPO Details Purpose of IPO: Anteris Technologies plans to use IPO proceeds to advance R&D for its flagship DurAVR transcatheter heart valve, expand production facilities, and boost global commercialization. Approximately $100 million of...